

CONTROLLED SUBSTANCE AMENDMENTS

2017 GENERAL SESSION

STATE OF UTAH

Chief Sponsor: Paul Ray

Senate Sponsor: Allen M. Christensen

Cosponsor: Carol Spackman Moss

LONG TITLE

General Description:

This bill modifies the Utah Controlled Substances Act.

Highlighted Provisions:

This bill:

► adds the following to the list of controlled substances under Schedule I:

- 3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-methylbenzamide, also known as U-47700 or "pink";
- Acetyl fentanyl: (N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide);
- Butyryl fentanyl: N-(1-(2-phenylethyl)-4-piperidiny)-N-phenylbutyramide;
- Furanyl fentanyl: and

N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]furan-2-carboxamide; and

► adds the following to listed controlled substances:

- ADB-CHMINACA: N-[(2S)-1-amino-3,3-dimethyl-1-oxobutan-2-yl]-1-(cyclohexylmethyl)indazole-3-carboxamide;
- ADB-FUBINACA: (N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide); and
- FUB-AMB; methyl (1-(4-fluorobenzyl)-1H-indazole-3-carbonyl)valinate.

Money Appropriated in this Bill:

None

Other Special Clauses:

This bill provides a special effective date.

Utah Code Sections Affected:

AMENDS:

58-37-4, as last amended by Laws of Utah 2015, Chapter 258

58-37-4.2, as last amended by Laws of Utah 2014, Chapter 23

Be it enacted by the Legislature of the state of Utah:

Section 1. Section **58-37-4** is amended to read:

58-37-4. Schedules of controlled substances -- Schedules I through V -- Findings required -- Specific substances included in schedules.

(1) There are established five schedules of controlled substances known as Schedules I, II, III, IV, and V which consist of substances listed in this section.

(2) Schedules I, II, III, IV, and V consist of the following drugs or other substances by the official name, common or usual name, chemical name, or brand name designated:

(a) Schedule I:

(i) Unless specifically excepted or unless listed in another schedule, any of the following opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, when the existence of the isomers, esters, ethers, and salts is possible within the specific chemical designation:

(A) Acetyl-alpha-methylfentanyl
(N-[1-(1-methyl-2-phenethyl)-4-piperidiny]-N-phenylacetamide);

(B) Acetyl fentanyl: (N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide);

~~[(B)]~~ (C) Acetylmethadol;

~~[(C)]~~ (D) Allylprodine;

~~[(D)]~~ (E) Alphacetylmethadol, except levo-alphacetylmethadol also known as levo-alpha-acetylmethadol, levomethadyl acetate, or LAAM;

~~[(E)]~~ (F) Alphameprodine;

~~[(F)]~~ (G) Alphamethadol;

- 57 ~~[(G)]~~ (H) Alpha-methylfentanyl (N-[1-(alpha-methyl-beta-phenyl)ethyl-4-piperidyl]
- 58 propionanilide; 1-(1-methyl-2-phenylethyl)-4-(N-propanilido) piperidine);
- 59 ~~[(H)]~~ (I) Alpha-methylthiofentanyl (N-[1-methyl-2-(2-thienyl)ethyl-4-
- 60 piperidinyl]-N-phenylpropanamide);
- 61 ~~[(I)]~~ (J) Benzylpiperazine;
- 62 ~~[(J)]~~ (K) Benzethidine;
- 63 ~~[(K)]~~ (L) Betacetylmethadol;
- 64 ~~[(L)]~~ (M) Beta-hydroxyfentanyl (N-[1-(2-hydroxy-2-phenethyl)-4-
- 65 piperidinyl]-N-phenylpropanamide);
- 66 ~~[(M)]~~ (N) Beta-hydroxy-3-methylfentanyl, other name: N-[1-(2-hydroxy-2-
- 67 phenethyl)-3-methyl-4-piperidinyl]-N-phenylpropanamide;
- 68 ~~[(N)]~~ (O) Betameprodine;
- 69 ~~[(O)]~~ (P) Betamethadol;
- 70 ~~[(P)]~~ (Q) Betaprodine;
- 71 (R) Butyryl fentanyl: N-(1-(2-phenylethyl)-4-piperidinyl)-N-phenylbutyramide;
- 72 ~~[(Q)]~~ (S) Clonitazene;
- 73 ~~[(R)]~~ (T) Dextromoramide;
- 74 ~~[(S)]~~ (U) Diampromide;
- 75 ~~[(T)]~~ (V) Diethylthiambutene;
- 76 ~~[(U)]~~ (W) Difenoxin;
- 77 ~~[(V)]~~ (X) Dimenoxadol;
- 78 ~~[(W)]~~ (Y) Dimepheptanol;
- 79 ~~[(X)]~~ (Z) Dimethylthiambutene;
- 80 ~~[(Y)]~~ (AA) Dioxaphetyl butyrate;
- 81 ~~[(Z)]~~ (BB) Dipipanone;
- 82 ~~[(AA)]~~ (CC) Ethylmethylthiambutene;
- 83 ~~[(BB)]~~ (DD) Etonitazene;
- 84 ~~[(CC)]~~ (EE) Etoperidine;

85 (FF) Furanyl fentanyl: N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]
 86 furan-2-carboxamide;
 87 [~~(DD)~~] (GG) Furethidine;
 88 [~~(EE)~~] (HH) Hydroxypethidine;
 89 [~~(FF)~~] (II) Ketobemidone;
 90 [~~(GG)~~] (JJ) Levomoramide;
 91 [~~(HH)~~] (KK) Levophenacymorphan;
 92 [~~(II)~~] (LL) Morpheridine;
 93 [~~(JJ)~~] (MM) MPPP (1-methyl-4-phenyl-4-propionoxypiperidine);
 94 [~~(KK)~~] (NN) Noracymethadol;
 95 [~~(LL)~~] (OO) Norlevorphanol;
 96 [~~(MM)~~] (PP) Normethadone;
 97 [~~(NN)~~] (QQ) Norpipanone;
 98 [~~(OO)~~] (RR) Para-fluorofentanyl (N-(4-fluorophenyl)-N-[1-(2-phenethyl)-4-
 99 piperidinyl] propanamide;
 100 [~~(PP)~~] (SS) PEPAP (1-(2-phenethyl)-4-phenyl-4-acetoxypiperidine);
 101 [~~(QQ)~~] (TT) Phenadoxone;
 102 [~~(RR)~~] (UU) Phenampromide;
 103 [~~(SS)~~] (VV) Phenomorphan;
 104 [~~(TT)~~] (WW) Phenoperidine;
 105 [~~(UU)~~] (XX) Piritramide;
 106 [~~(VV)~~] (YY) Proheptazine;
 107 [~~(WW)~~] (ZZ) Properidine;
 108 [~~(XX)~~] (AAA) Propiram;
 109 [~~(YY)~~] (BBB) Racemoramide;
 110 [~~(ZZ)~~] (CCC) Thiofentanyl (N-phenyl-N-[1-(2-thienyl)ethyl-4-piperidinyl]-
 111 propanamide;
 112 [~~(AAA)~~] (DDD) Tilidine;

113 ~~[(BBB)]~~ (EEE) Trimeperidine;
114 ~~[(CCC)]~~ (FFF) 3-methylfentanyl, including the optical and geometric isomers
115 (N-[3-methyl-1-(2-phenylethyl)-4-piperidyl]- N-phenylpropanamide); ~~[and]~~
116 ~~[(DDD)]~~ (GGG) 3-methylthiofentanyl
117 (N-[(3-methyl-1-(2-thienyl)ethyl-4-piperidinyl]-N-phenylpropanamide)[-]; and
118 ~~[(EEE)]~~ (HHH) 3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-methylbenzamide
119 also known as U-47700.

120 (ii) Unless specifically excepted or unless listed in another schedule, any of the
121 following opium derivatives, their salts, isomers, and salts of isomers when the existence of the
122 salts, isomers, and salts of isomers is possible within the specific chemical designation:

- 123 (A) Acetorphine;
124 (B) Acetyldihydrocodeine;
125 (C) Benzylmorphine;
126 (D) Codeine methylbromide;
127 (E) Codeine-N-Oxide;
128 (F) Cyprenorphine;
129 (G) Desomorphine;
130 (H) Dihydromorphine;
131 (I) Drotebanol;
132 (J) Etorphine (except hydrochloride salt);
133 (K) Heroin;
134 (L) Hydromorphinol;
135 (M) Methyldesorphine;
136 (N) Methylhydromorphine;
137 (O) Morphine methylbromide;
138 (P) Morphine methylsulfonate;
139 (Q) Morphine-N-Oxide;
140 (R) Myrophine;

- 141 (S) Nicocodeine;
142 (T) Nicomorphine;
143 (U) Normorphine;
144 (V) Pholcodine; and
145 (W) Thebacon.
- 146 (iii) Unless specifically excepted or unless listed in another schedule, any material,
147 compound, mixture, or preparation which contains any quantity of the following hallucinogenic
148 substances, or which contains any of their salts, isomers, and salts of isomers when the
149 existence of the salts, isomers, and salts of isomers is possible within the specific chemical
150 designation; as used in this Subsection (2)(a)(iii) only, "isomer" includes the optical, position,
151 and geometric isomers:
- 152 (A) Alpha-ethyltryptamine, some trade or other names: etryptamine; Monase;
153 α -ethyl-1H-indole-3-ethanamine; 3-(2-aminobutyl) indole; α -ET; and AET;
- 154 (B) 4-bromo-2,5-dimethoxy-amphetamine, some trade or other names:
155 4-bromo-2,5-dimethoxy- α -methylphenethylamine; 4-bromo-2,5-DMA;
- 156 (C) 4-bromo-2,5-dimethoxyphenethylamine, some trade or other names:
157 2-(4-bromo-2,5-dimethoxyphenyl)-1-aminoethane; alpha-desmethyl DOB; 2C-B, Nexus;
- 158 (D) 2,5-dimethoxyamphetamine, some trade or other names:
159 2,5-dimethoxy- α -methylphenethylamine; 2,5-DMA;
- 160 (E) 2,5-dimethoxy-4-ethylamphetamine, some trade or other names: DOET;
- 161 (F) 4-methoxyamphetamine, some trade or other names:
162 4-methoxy- α -methylphenethylamine; paramethoxyamphetamine, PMA;
- 163 (G) 5-methoxy-3,4-methylenedioxyamphetamine;
- 164 (H) 4-methyl-2,5-dimethoxy-amphetamine, some trade and other names:
165 4-methyl-2,5-dimethoxy- α -methylphenethylamine; "DOM"; and "STP";
- 166 (I) 3,4-methylenedioxy amphetamine;
- 167 (J) 3,4-methylenedioxymethamphetamine (MDMA);
- 168 (K) 3,4-methylenedioxy-N-ethylamphetamine, also known as N-ethyl-

169 alpha-methyl-3,4(methylenedioxy)phenethylamine, N-ethyl MDA, MDE, MDEA;
170 (L) N-hydroxy-3,4-methylenedioxyamphetamine, also known as
171 N-hydroxy-alpha-methyl-3,4(methylenedioxy)phenethylamine, and N-hydroxy MDA;
172 (M) 3,4,5-trimethoxy amphetamine;
173 (N) Bufotenine, some trade and other names:
174 3-(β -Dimethylaminoethyl)-5-hydroxyindole; 3-(2-dimethylaminoethyl)-5-indolol; N,
175 N-dimethylserotonin; 5-hydroxy-N,N-dimethyltryptamine; mappine;
176 (O) Diethyltryptamine, some trade and other names: N,N-Diethyltryptamine; DET;
177 (P) Dimethyltryptamine, some trade or other names: DMT;
178 (Q) Ibogaine, some trade and other names:
179 7-Ethyl-6,6 β ,7,8,9,10,12,13-octahydro-2-methoxy-6,9-methano-5H-pyrido [1', 2':1,2] azepino
180 [5,4-b] indole; Tabernanthe iboga;
181 (R) Lysergic acid diethylamide;
182 (S) Marijuana;
183 (T) Mescaline;
184 (U) Parahexyl, some trade or other names:
185 3-Hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-dibenzo[b,d]pyran; Synhexyl;
186 (V) Peyote, meaning all parts of the plant presently classified botanically as
187 *Lophophora williamsii* Lemaire, whether growing or not, the seeds thereof, any extract from
188 any part of such plant, and every compound, manufacture, salts, derivative, mixture, or
189 preparation of such plant, its seeds or extracts (Interprets 21 USC 812(c), Schedule I(c) (12));
190 (W) N-ethyl-3-piperidyl benzilate;
191 (X) N-methyl-3-piperidyl benzilate;
192 (Y) Psilocybin;
193 (Z) Psilocyn;
194 (AA) Tetrahydrocannabinols, naturally contained in a plant of the genus *Cannabis*
195 (*cannabis* plant), as well as synthetic equivalents of the substances contained in the *cannabis*
196 plant, or in the resinous extractives of *Cannabis*, sp. and/or synthetic substances, derivatives,

and their isomers with similar chemical structure and pharmacological activity to those substances contained in the plant, such as the following: Δ^1 cis or trans tetrahydrocannabinol, and their optical isomers Δ^6 cis or trans tetrahydrocannabinol, and their optical isomers $\Delta^3,4$ cis or trans tetrahydrocannabinol, and its optical isomers, and since nomenclature of these substances is not internationally standardized, compounds of these structures, regardless of numerical designation of atomic positions covered;

(BB) Ethylamine analog of phencyclidine, some trade or other names:

N-ethyl-1-phenylcyclohexylamine, (1-phenylcyclohexyl)ethylamine,
N-(1-phenylcyclohexyl)ethylamine, cyclohexamine, PCE;

(CC) Pyrrolidine analog of phencyclidine, some trade or other names:

1-(1-phenylcyclohexyl)-pyrrolidine, PCPy, PHP;

(DD) Thiophene analog of phencyclidine, some trade or other names:

1-[1-(2-thienyl)-cyclohexyl]-piperidine, 2-thienylanalog of phencyclidine, TCP, TCP; and

(EE) 1-[1-(2-thienyl)cyclohexyl]pyrrolidine, some other names: TCPy.

(iv) Unless specifically excepted or unless listed in another schedule, any material compound, mixture, or preparation which contains any quantity of the following substances having a depressant effect on the central nervous system, including its salts, isomers, and salts of isomers when the existence of the salts, isomers, and salts of isomers is possible within the specific chemical designation:

(A) Mecloqualone; and

(B) Methaqualone.

(v) Any material, compound, mixture, or preparation containing any quantity of the following substances having a stimulant effect on the central nervous system, including their salts, isomers, and salts of isomers:

(A) Aminorex, some other names: aminoxaphen; 2-amino-5-phenyl-2-oxazoline; or 4,5-dihydro-5-phenyl-2-oxazolamine;

(B) Cathinone, some trade or other names: 2-amino-1-phenyl-1-propanone, alpha-aminopropiophenone, 2-aminopropiophenone, and norephedrone;

- 225 (C) Fenethylamine;
- 226 (D) Methcathinone, some other names: 2-(methylanino)-propiofenone;
- 227 α -(methylanino)propiofenone; 2-(methylanino)-1-phenylpropan-1-one;
- 228 α -N-methylaminopropiofenone; monomethylpropion; ephedrone; N-methylcathinone;
- 229 methylcathinone; AL-464; AL-422; AL-463 and UR1432, its salts, optical isomers, and salts of
- 230 optical isomers;
- 231 (E) ($\pm$)cis-4-methylaminorex (($\pm$)cis-4,5-dihydro-4-methyl-5-phenyl-2-oxazolamine);
- 232 (F) N-ethylamphetamine; and
- 233 (G) N,N-dimethylamphetamine, also known as
- 234 N,N- α -trimethyl-benzeneethanamine; N,N- α -trimethylphenethylamine.
- 235 (vi) Any material, compound, mixture, or preparation which contains any quantity of
- 236 the following substances, including their optical isomers, salts, and salts of isomers, subject to
- 237 temporary emergency scheduling:
- 238 (A) N-[1-benzyl-4-piperidyl]-N-phenylpropanamide (benzylfentanyl); and
- 239 (B) N-[1-(2-thienyl)methyl-4-piperidyl]-N-phenylpropanamide (thenylfentanyl).
- 240 (vii) Unless specifically excepted or unless listed in another schedule, any material,
- 241 compound, mixture, or preparation which contains any quantity of gamma hydroxy butyrate
- 242 (gamma hydrobutyric acid), including its salts, isomers, and salts of isomers.
- 243 (b) Schedule II:
- 244 (i) Unless specifically excepted or unless listed in another schedule, any of the
- 245 following substances whether produced directly or indirectly by extraction from substances of
- 246 vegetable origin, or independently by means of chemical synthesis, or by a combination of
- 247 extraction and chemical synthesis:
- 248 (A) Opium and opiate, and any salt, compound, derivative, or preparation of opium or
- 249 opiate, excluding apomorphine, dextrorphan, nalbuphine, nalmeffene, naloxone, and naltrexone,
- 250 and their respective salts, but including:
- 251 (I) Raw opium;
- 252 (II) Opium extracts;

- 253 (III) Opium fluid;
254 (IV) Powdered opium;
255 (V) Granulated opium;
256 (VI) Tincture of opium;
257 (VII) Codeine;
258 (VIII) Ethylmorphine;
259 (IX) Etorphine hydrochloride;
260 (X) Hydrocodone;
261 (XI) Hydromorphone;
262 (XII) Metopon;
263 (XIII) Morphine;
264 (XIV) Oxycodone;
265 (XV) Oxymorphone; and
266 (XVI) Thebaine;
267 (B) Any salt, compound, derivative, or preparation which is chemically equivalent or
268 identical with any of the substances referred to in Subsection (2)(b)(i)(A), except that these
269 substances may not include the isoquinoline alkaloids of opium;
270 (C) Opium poppy and poppy straw;
271 (D) Coca leaves and any salt, compound, derivative, or preparation of coca leaves, and
272 any salt, compound, derivative, or preparation which is chemically equivalent or identical with
273 any of these substances, and includes cocaine and ecgonine, their salts, isomers, derivatives,
274 and salts of isomers and derivatives, whether derived from the coca plant or synthetically
275 produced, except the substances may not include decocainized coca leaves or extraction of coca
276 leaves, which extractions do not contain cocaine or ecgonine; and
277 (E) Concentrate of poppy straw, which means the crude extract of poppy straw in either
278 liquid, solid, or powder form which contains the phenanthrene alkaloids of the opium poppy.
279 (ii) Unless specifically excepted or unless listed in another schedule, any of the
280 following opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters, and

281 ethers, when the existence of the isomers, esters, ethers, and salts is possible within the specific
282 chemical designation, except dextrorphan and levopropoxyphene:

- 283 (A) Alfentanil;
- 284 (B) Alphaprodine;
- 285 (C) Anileridine;
- 286 (D) Bezitramide;
- 287 (E) Bulk dextropropoxyphene (nondosage forms);
- 288 (F) Carfentanil;
- 289 (G) Dihydrocodeine;
- 290 (H) Diphenoxylate;
- 291 (I) Fentanyl;
- 292 (J) Isomethadone;
- 293 (K) Levo-alpha-acetylmethadol, some other names: levo-alpha-acetylmethadol,
294 levomethadyl acetate, or LAAM;
- 295 (L) Levomethorphan;
- 296 (M) Levorphanol;
- 297 (N) Metazocine;
- 298 (O) Methadone;
- 299 (P) Methadone-Intermediate, 4-cyano-2-dimethylamino-4, 4-diphenyl butane;
- 300 (Q) Moramide-Intermediate, 2-methyl-3-morpholino-1, 1-diphenylpropane-carboxylic
301 acid;
- 302 (R) Pethidine (meperidine);
- 303 (S) Pethidine-Intermediate-A, 4-cyano-1-methyl-4-phenylpiperidine;
- 304 (T) Pethidine-Intermediate-B, ethyl-4-phenylpiperidine-4-carboxylate;
- 305 (U) Pethidine-Intermediate-C, 1-methyl-4-phenylpiperidine-4-carboxylic acid;
- 306 (V) Phenazocine;
- 307 (W) Piminodine;
- 308 (X) Racemethorphan;

- 309 (Y) Racemorphan;
310 (Z) Remifentanyl; and
311 (AA) Sufentanyl.
- 312 (iii) Unless specifically excepted or unless listed in another schedule, any material,
313 compound, mixture, or preparation which contains any quantity of the following substances
314 having a stimulant effect on the central nervous system:
- 315 (A) Amphetamine, its salts, optical isomers, and salts of its optical isomers;
316 (B) Methamphetamine, its salts, isomers, and salts of its isomers;
317 (C) Phenmetrazine and its salts; and
318 (D) Methylphenidate.
- 319 (iv) Unless specifically excepted or unless listed in another schedule, any material,
320 compound, mixture, or preparation which contains any quantity of the following substances
321 having a depressant effect on the central nervous system, including its salts, isomers, and salts
322 of isomers when the existence of the salts, isomers, and salts of isomers is possible within the
323 specific chemical designation:
- 324 (A) Amobarbital;
325 (B) Glutethimide;
326 (C) Pentobarbital;
327 (D) Phencyclidine;
328 (E) Phencyclidine immediate precursors: 1-phenylcyclohexylamine and
329 1-piperidinocyclohexanecarbonitrile (PCC); and
330 (F) Secobarbital.
- 331 (v) (A) Unless specifically excepted or unless listed in another schedule, any material,
332 compound, mixture, or preparation which contains any quantity of Phenylacetone.
333 (B) Some of these substances may be known by trade or other names:
334 phenyl-2-propanone; P2P; benzyl methyl ketone; and methyl benzyl ketone.
- 335 (vi) Nabilone, another name for nabilone:
336 (±)-trans-3-(1,1-dimethylheptyl)-6,6a,7,8,10,10a-hexahydro-1-hydroxy-6,

6-dimethyl-9H-dibenzo[b,d]pyran-9-one.

(c) Schedule III:

(i) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers whether optical, position, or geometric, and salts of the isomers when the existence of the salts, isomers, and salts of isomers is possible within the specific chemical designation:

(A) Those compounds, mixtures, or preparations in dosage unit form containing any stimulant substances listed in Schedule II, which compounds, mixtures, or preparations were listed on August 25, 1971, as excepted compounds under Section 1308.32 of Title 21 of the Code of Federal Regulations, and any other drug of the quantitative composition shown in that list for those drugs or which is the same except that it contains a lesser quantity of controlled substances;

(B) Benzphetamine;

(C) Chlorphentermine;

(D) Clortermine; and

(E) Phendimetrazine.

(ii) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a depressant effect on the central nervous system:

(A) Any compound, mixture, or preparation containing amobarbital, secobarbital, pentobarbital, or any salt of any of them, and one or more other active medicinal ingredients which are not listed in any schedule;

(B) Any suppository dosage form containing amobarbital, secobarbital, or pentobarbital, or any salt of any of these drugs which is approved by the Food and Drug Administration for marketing only as a suppository;

(C) Any substance which contains any quantity of a derivative of barbituric acid or any salt of any of them;

- 365 (D) Chlorhexadol;
- 366 (E) Buprenorphine;
- 367 (F) Any drug product containing gamma hydroxybutyric acid, including its salts,
368 isomers, and salts of isomers, for which an application is approved under the federal Food,
369 Drug, and Cosmetic Act, Section 505;
- 370 (G) Ketamine, its salts, isomers, and salts of isomers, some other names for ketamine:
371 $\pm$ -2-(2-chlorophenyl)-2-(methylamino)-cyclohexanone;
- 372 (H) Lysergic acid;
- 373 (I) Lysergic acid amide;
- 374 (J) Methypylon;
- 375 (K) Sulfondiethylmethane;
- 376 (L) Sulfonethylmethane;
- 377 (M) Sulfonmethane; and
- 378 (N) Tiletamine and zolazepam or any of their salts, some trade or other names for a
379 tiletamine-zolazepam combination product: Telazol, some trade or other names for tiletamine:
380 2-(ethylamino)-2-(2-thienyl)-cyclohexanone, some trade or other names for zolazepam:
381 4-(2-fluorophenyl)-6,8-dihydro-1,3,8-trimethylpyrazolo-[3,4-e] [1,4]-diazepin-7(1H)-one,
382 flupyrzapon.
- 383 (iii) Dronabinol (synthetic) in sesame oil and encapsulated in a soft gelatin capsule in a
384 U.S. Food and Drug Administration approved drug product, some other names for dronabinol:
385 (6aR-trans)-6a,7,8,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-6H-dibenzo[b,d]pyran-1-ol, or
386 (-)-delta-9-(trans)-tetrahydrocannabinol.
- 387 (iv) Nalorphine.
- 388 (v) Unless specifically excepted or unless listed in another schedule, any material,
389 compound, mixture, or preparation containing limited quantities of any of the following
390 narcotic drugs, or their salts calculated as the free anhydrous base or alkaloid:
- 391 (A) Not more than 1.8 grams of codeine per 100 milliliters or not more than 90
392 milligrams per dosage unit, with an equal or greater quantity of an isoquinoline alkaloid of

393 opium;

394 (B) Not more than 1.8 grams of codeine per 100 milliliters or not more than 90
395 milligrams per dosage unit, with one or more active non-narcotic ingredients in recognized
396 therapeutic amounts;

397 (C) Not more than 300 milligrams of dihydrocodeinone per 100 milliliters or not more
398 than 15 milligrams per dosage unit, with a fourfold or greater quantity of an isoquinoline
399 alkaloid of opium;

400 (D) Not more than 300 milligrams of dihydrocodeinone per 100 milliliters or not more
401 than 15 milligrams per dosage unit, with one or more active, non-narcotic ingredients in
402 recognized therapeutic amounts;

403 (E) Not more than 1.8 grams of dihydrocodeine per 100 milliliters or not more than 90
404 milligrams per dosage unit, with one or more active non-narcotic ingredients in recognized
405 therapeutic amounts;

406 (F) Not more than 300 milligrams of ethylmorphine per 100 milliliters or not more
407 than 15 milligrams per dosage unit, with one or more active, non-narcotic ingredients in
408 recognized therapeutic amounts;

409 (G) Not more than 500 milligrams of opium per 100 milliliters or per 100 grams, or not
410 more than 25 milligrams per dosage unit, with one or more active, non-narcotic ingredients in
411 recognized therapeutic amounts; and

412 (H) Not more than 50 milligrams of morphine per 100 milliliters or per 100 grams with
413 one or more active, non-narcotic ingredients in recognized therapeutic amounts.

414 (vi) Unless specifically excepted or unless listed in another schedule, anabolic steroids
415 including any of the following or any isomer, ester, salt, or derivative of the following that
416 promotes muscle growth:

417 (A) Boldenone;

418 (B) Chlorotestosterone (4-chlortestosterone);

419 (C) Clostebol;

420 (D) Dehydrochlormethyltestosterone;

- 421 (E) Dihydrotestosterone (4-dihydrotestosterone);
422 (F) Drostanolone;
423 (G) Ethylestrenol;
424 (H) Fluoxymesterone;
425 (I) Formebolone (formebolone);
426 (J) Mesterolone;
427 (K) Methandienone;
428 (L) Methandranone;
429 (M) Methandriol;
430 (N) Methandrostenolone;
431 (O) Methenolone;
432 (P) Methyltestosterone;
433 (Q) Mibolerone;
434 (R) Nandrolone;
435 (S) Norethandrolone;
436 (T) Oxandrolone;
437 (U) Oxymesterone;
438 (V) Oxymetholone;
439 (W) Stanolone;
440 (X) Stanozolol;
441 (Y) Testolactone;
442 (Z) Testosterone; and
443 (AA) Trenbolone.
444 (vii) Anabolic steroids expressly intended for administration through implants to cattle
445 or other nonhuman species, and approved by the Secretary of Health and Human Services for
446 use, may not be classified as a controlled substance.
447 (d) Schedule IV:
448 (i) Unless specifically excepted or unless listed in another schedule, any material,

449 compound, mixture, or preparation containing not more than 1 milligram of difenoxin and not
450 less than 25 micrograms of atropine sulfate per dosage unit, or any salts of any of them.

451 (ii) Unless specifically excepted or unless listed in another schedule, any material,
452 compound, mixture, or preparation which contains any quantity of the following substances,
453 including its salts, isomers, and salts of isomers when the existence of the salts, isomers, and
454 salts of isomers is possible within the specific chemical designation:

455 (A) Alprazolam;

456 (B) Barbital;

457 (C) Bromazepam;

458 (D) Butorphanol;

459 (E) Camazepam;

460 (F) Carisoprodol;

461 (G) Chloral betaine;

462 (H) Chloral hydrate;

463 (I) Chlordiazepoxide;

464 (J) Clobazam;

465 (K) Clonazepam;

466 (L) Clorazepate;

467 (M) Clotiazepam;

468 (N) Cloxazolam;

469 (O) Delorazepam;

470 (P) Diazepam;

471 (Q) Dichloralphenazone;

472 (R) Estazolam;

473 (S) Ethchlorvynol;

474 (T) Ethinamate;

475 (U) Ethyl loflazepate;

476 (V) Fludiazepam;

477 (W) Flunitrazepam;
478 (X) Flurazepam;
479 (Y) Halazepam;
480 (Z) Haloxazolam;
481 (AA) Ketazolam;
482 (BB) Loprazolam;
483 (CC) Lorazepam;
484 (DD) Lormetazepam;
485 (EE) Mebutamate;
486 (FF) Medazepam;
487 (GG) Meprobamate;
488 (HH) Methohexital;
489 (II) Methylphenobarbital (mephobarbital);
490 (JJ) Midazolam;
491 (KK) Nimetazepam;
492 (LL) Nitrazepam;
493 (MM) Nordiazepam;
494 (NN) Oxazepam;
495 (OO) Oxazolam;
496 (PP) Paraldehyde;
497 (QQ) Pentazocine;
498 (RR) Petrichloral;
499 (SS) Phenobarbital;
500 (TT) Pinazepam;
501 (UU) Prazepam;
502 (VV) Quazepam;
503 (WW) Temazepam;
504 (XX) Tetrazepam;

505 (YY) Triazolam;
506 (ZZ) Zaleplon; and
507 (AAA) Zolpidem.

508 (iii) Any material, compound, mixture, or preparation of fenfluramine which contains
509 any quantity of the following substances, including its salts, isomers whether optical, position,
510 or geometric, and salts of the isomers when the existence of the salts, isomers, and salts of
511 isomers is possible.

512 (iv) Unless specifically excepted or unless listed in another schedule, any material,
513 compound, mixture, or preparation which contains any quantity of the following substances
514 having a stimulant effect on the central nervous system, including its salts, isomers whether
515 optical, position, or geometric isomers, and salts of the isomers when the existence of the salts,
516 isomers, and salts of isomers is possible within the specific chemical designation:

- 517 (A) Cathine ((+)-norpseudoephedrine);
518 (B) Diethylpropion;
519 (C) Fencamfamine;
520 (D) Fenproporex;
521 (E) Mazindol;
522 (F) Mefenorex;
523 (G) Modafinil;
524 (H) Pemoline, including organometallic complexes and chelates thereof;
525 (I) Phentermine;
526 (J) Pipradrol;
527 (K) Sibutramine; and
528 (L) SPA ((-)-1-dimethylamino-1,2-diphenylethane).

529 (v) Unless specifically excepted or unless listed in another schedule, any material,
530 compound, mixture, or preparation which contains any quantity of dextropropoxyphene
531 (alpha-(+)-4-dimethylamino-1, 2-diphenyl-3-methyl-2-propionoxybutane), including its salts.

532 (e) Schedule V: Any compound, mixture, or preparation containing any of the

following limited quantities of narcotic drugs, or their salts calculated as the free anhydrous base or alkaloid, which includes one or more non-narcotic active medicinal ingredients in sufficient proportion to confer upon the compound, mixture, or preparation valuable medicinal qualities other than those possessed by the narcotic drug alone:

(i) not more than 200 milligrams of codeine per 100 milliliters or per 100 grams;

(ii) not more than 100 milligrams of dihydrocodeine per 100 milliliters or per 100 grams;

(iii) not more than 100 milligrams of ethylmorphine per 100 milliliters or per 100 grams;

(iv) not more than 2.5 milligrams of diphenoxylate and not less than 25 micrograms of atropine sulfate per dosage unit;

(v) not more than 100 milligrams of opium per 100 milliliters or per 100 grams;

(vi) not more than 0.5 milligram of difenoxin and not less than 25 micrograms of atropine sulfate per dosage unit;

(vii) unless specifically exempted or excluded or unless listed in another schedule, any material, compound, mixture, or preparation which contains Pyrovalerone having a stimulant effect on the central nervous system, including its salts, isomers, and salts of isomers; and

(viii) all forms of Tramadol.

Section 2. Section **58-37-4.2** is amended to read:

58-37-4.2. Listed controlled substances.

The following substances, their analogs, homologs, and synthetic equivalents are listed controlled substances:

(1) AB-001;

(2) AB-PINACA;

N-[1-(aminocarbonyl)-2-methylpropyl]-1-pentyl-1H-indazole-3-carboxamide;

(3) AB-FUBINACA; N-[1-(aminocarbonyl)-2-methylpropyl]-1-[(4-fluorophenyl) methyl]-1H-indazole-3-carboxamide;

(4) ADB-CHMINACA: N-[(2S)-1-amino-3,3-dimethyl-1-oxobutan-2-yl]-1-

561 (cyclohexylmethyl)indazole-3-carboxamide;
562 (5) ADB-FUBINACA: (N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-
563 (4-fluorobenzyl)-1H-indazole-3-carboxamide);
564 ~~[(4)]~~ (6) AKB48;
565 ~~[(5)]~~ (7) alpha-Pyrrolidinovalerophenone (alpha-PVP);
566 ~~[(6)]~~ (8) AM-694; 1-[(5-fluoropentyl)-1H-indol-3-yl]-(2-iodophenyl)methanone;
567 ~~[(7)]~~ (9) AM-1248;
568 ~~[(8)]~~ (10) AM-2201; 1-(5-fluoropentyl)-3-(1-naphthoyl)indole;
569 ~~[(9)]~~ (11) AM-2233;
570 ~~[(10)]~~ (12) AM-679;
571 ~~[(11)]~~ (13) A796,260;
572 ~~[(12)]~~ (14) Butylone;
573 ~~[(13)]~~ (15) CP 47,497 and its C6, C8, and C9 homologs;
574 2-[(1R,3S)-3-hydroxycyclohexyl]-5-(2-methyloctan-2-yl)phenol;
575 ~~[(14)]~~ (16) Diisopropyltryptamine (DiPT);
576 ~~[(15)]~~ (17) Ethylone;
577 ~~[(16)]~~ (18) Ethylphenidate;
578 ~~[(17)]~~ (19) Fluoroisocathinone;
579 ~~[(18)]~~ (20) Fluoromethamphetamine;
580 ~~[(19)]~~ (21) Fluoromethcathinone;
581 (22) FUB-AMB; methyl (1-(4-fluorobenzyl)-1H-indazole-3-carbonyl)valinate;
582 ~~[(20)]~~ (23) HU-210;
583 (6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)
584 -6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol;
585 ~~[(21)]~~ (24) HU-211; Dexanabinol,(6aS,10aS)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-
586 methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol;
587 ~~[(22)]~~ (25) JWH-015; (2-methyl-1-propyl-1H-indol-3-yl)-1-naphthalenyl-methanone;
588 ~~[(23)]~~ (26) JWH-018; Naphthalen-1-yl-(pentylindol-3-yl)methanone {also known as

589 1-Pentyl-3-(1-naphthoyl)indole};
590 [~~(24)~~] (27) JWH-019; 1-hexyl-3-(1-naphthoyl)indole;
591 [~~(25)~~] (28) JWH-073; Naphthalen-1-yl(1-butylindol-3-yl)methanone {also known as
592 1-Butyl-3-(1-naphthoyl)indole};
593 [~~(26)~~] (29) JWH-081; 4-methoxynaphthalen-1-yl-(1-pentylindol-3-yl)methanone;
594 [~~(27)~~] (30) JWH-122; CAS#619294-47-2; (1-Pentyl-3-(4-methyl-1-naphthoyl)indole);
595 [~~(28)~~] (31) JWH-200; 1-(2-(4-(morpholinyl)ethyl))-3-(1-naphthoyl)indole;
596 [~~(29)~~] (32) JWH-203; 1-pentyl-3-(2-chlorophenylacetyl)indole;
597 [~~(30)~~] (33) JWH-210; 4-ethyl-1-naphthalenyl(1-pentyl-1H-indol-3-yl)-methanone;
598 [~~(31)~~] (34) JWH-250; 1-pentyl-3-(2-methoxyphenylacetyl)indole;
599 [~~(32)~~] (35) JWH-251; 2-(2-methylphenyl)-1-(1-pentyl-1H-indol-3-yl)ethanone;
600 [~~(33)~~] (36) JWH-398; 1-pentyl-3-(4-chloro-1-naphthoyl)indole;
601 [~~(34)~~] (37) MAM-2201;
602 [~~(35)~~] (38) MAM-2201;
603 (1-(5-fluoropentyl)-1H-indol-3-yl)(4-ethyl-1-naphthalenyl)-methanone;
604 [~~(36)~~] (39) Methoxetamine;
605 [~~(37)~~] (40) Naphyrone;
606 [~~(38)~~] (41) PB-22; 1-pentyl-1H-indole-3-carboxylic acid 8-quinolinyl ester;
607 [~~(39)~~] (42) Pentedrone;
608 [~~(40)~~] (43) Pentylone;
609 [~~(41)~~] (44) RCS-4; 1-pentyl-3-(4-methoxybenzoyl)indole;
610 [~~(42)~~] (45) RCS-8; 1-(2-cyclohexylethyl)-3-(2-methoxyphenylacetyl)indole {also
611 known as BTW-8 and SR-18};
612 [~~(43)~~] (46) STS-135;
613 [~~(44)~~] (47) UR-144;
614 [~~(45)~~] (48) UR-144 N-(5-chloropentyl) analog;
615 [~~(46)~~] (49) XLR11;
616 [~~(47)~~] (50) 2C-C;

617 [~~(48)~~] (51) 2C-D;
618 [~~(49)~~] (52) 2C-E;
619 [~~(50)~~] (53) 2C-H;
620 [~~(51)~~] (54) 2C-I;
621 [~~(52)~~] (55) 2C-N;
622 [~~(53)~~] (56) 2C-P;
623 [~~(54)~~] (57) 2C-T-2;
624 [~~(55)~~] (58) 2C-T-4;
625 [~~(56)~~] (59) 2NE1;
626 [~~(57)~~] (60) 25I-NBOMe;
627 [~~(58)~~] (61) 2,5-Dimethoxy-4-chloroamphetamine (DOC);
628 [~~(59)~~] (62) 4-methylmethcathinone {also known as mephedrone};
629 [~~(60)~~] (63) 3,4-methylenedioxypyrovalerone {also known as MDPV};
630 [~~(61)~~] (64) 3,4-Methylenedioxymethcathinone {also known as methyone};
631 [~~(62)~~] (65) 4-methoxymethcathinone;
632 [~~(63)~~] (66) 4-Methyl-alpha-pyrrolidinopropiophenone;
633 [~~(64)~~] (67) 4-Methylethcathinone;
634 [~~(65)~~] (68) 5F-AKB48;
635 1-(5-fluoropentyl)-N-tricyclo[3.3.1.1^{3,7}]dec-1-yl-1H-indazole-3- carboxamide;
636 [~~(66)~~] (69) 5-fluoro-PB-22; 1-(5-fluoropentyl)-1H-indole-3-carboxylic acid
637 8-quinolinyl ester;
638 [~~(67)~~] (70) 5-Iodo-2-aminoindane (5-IAI);
639 [~~(68)~~] (71) 5-MeO-DALT;
640 [~~(69)~~] (72) 25B-NBOMe; 2-(4-bromo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)
641 methyl]ethanamine;
642 [~~(70)~~] (73) 25C-NBOMe; 2-(4-Chloro-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)
643 methyl]ethanamine; and
644 [~~(71)~~] (74) 25H-NBOMe;

645 2-(2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine.

646 Section 3. **Effective date.**

647 If approved by two-thirds of all the members elected to each house, this bill takes effect
648 upon approval by the governor, or the day following the constitutional time limit of Utah
649 Constitution, Article VII, Section 8, without the governor's signature, or in the case of a veto,
650 the date of veto override.